Next Article in Journal
Fibrotic Hypersensitivity Pneumonitis: Key Issues in Diagnosis and Management
Previous Article in Journal
Social Factors Determine the Emergency Medical Admission Workload
Article Menu
Issue 6 (June) cover image

Export Article

Open AccessReview
J. Clin. Med. 2017, 6(6), 61; doi:10.3390/jcm6060061

Renin Inhibition with Aliskiren: A Decade of Clinical Experience

1
Medical School, University of Patras, Rio Achaia 26504, Greece
2
Department of Medicine, Schools of Health Sciences, University of Athens75 Mikras Asias str., Athens 11527, Greece
3
Internal Medicine Department, University Hospital of Patras, Rio Achaia 26504, Greece
*
Author to whom correspondence should be addressed.
Academic Editor: Jane Grant-Kels
Received: 22 March 2017 / Revised: 24 May 2017 / Accepted: 3 June 2017 / Published: 9 June 2017
View Full-Text   |   Download PDF [458 KB, uploaded 12 June 2017]   |  

Abstract

The renin-angiotensin-aldosterone system (RAAS) plays a key role in the pathophysiology of arterial hypertension as well as in more complex mechanisms of cardiovascular and renal diseases. RAAS-blocking agents like angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers, have long been key components in the treatment of essential hypertension, heart failure, diabetic nephropathy, and chronic kidney disease, showing benefits well beyond blood pressure reduction. Renin blockade as the first step of the RAAS cascade finally became possible in 2007 with the approval of aliskiren, the first orally active direct renin inhibitor available for clinical use and the newest antihypertensive agent on the market. In the last decade, many clinical trials and meta-analyses have been conducted concerning the efficacy and safety of aliskiren in comparison to other antihypertensive agents, as well as the efficacy and potential clinical use of various combinations. Large trials with cardiovascular and renal endpoints attempted to show potential benefits of aliskiren beyond blood pressure lowering, as well as morbidity and mortality outcomes in specific populations such as diabetics, heart failure patients, and post-myocardial infarction individuals. The purpose of this review is to present the currently available data regarding established and future potential clinical uses of aliskiren. View Full-Text
Keywords: aliskiren; hypertension; direct renin inhibitors; renin-angiotensin-aldosterone system aliskiren; hypertension; direct renin inhibitors; renin-angiotensin-aldosterone system
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Pantzaris, N.-D.; Karanikolas, E.; Tsiotsios, K.; Velissaris, D. Renin Inhibition with Aliskiren: A Decade of Clinical Experience. J. Clin. Med. 2017, 6, 61.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top